19 results
DEF 14A
SLRN
Acelyrin Inc
22 Apr 24
Definitive proxy
4:10pm
Committee requested that Aon:
evaluate the efficacy of our existing compensation strategy and practices in supporting and reinforcing our long-term strategic … strategy and practices in supporting and reinforcing our long-term strategic goals;
assist the Compensation Committee in refining the Company’s
10-K
2023 FY
SLRN
Acelyrin Inc
28 Mar 24
Annual report
4:21pm
of the treatment period at week 32. In March 2024, we announced long-term (week 32) data from such trial, in which we observed rapid dose-ordered … , participants that previously received placebo receive izokibep for the remainder of the 52-week trial period.
The long-term follow up period
8-K
EX-99.1
SLRN
Acelyrin Inc
28 Mar 24
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
4:08pm
hurdle endpoints
Announced differentiated long-term 32-week data from global Phase 2b clinical trial of izokibep in hidradenitis suppurativa – ongoing … long-term data for izokibep in a global Phase 2b clinical trial in HS with results demonstrating rapid, dose ordered improvement across multiple
8-K
SLRN
Acelyrin Inc
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
. Announces Long-Term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening … , titled “ACELYRIN, INC. Announces Long-Term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained
8-K
EX-99.2
rpbcd8hlrsbohphp
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.3
xx3d7
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
zlvmvcr b6ralqg
11 Mar 24
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
8:05am
8-K
EX-99.1
zin vtta7
27 Nov 23
ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program
4:31pm
8-K
EX-99
2e9rljdw1hkwu1 i4m
7 Nov 23
ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights
4:23pm
10-Q
gsbhuask4cshxftykvyf
15 Jun 23
Quarterly report
4:19pm
424B4
ltr3 v798
5 May 23
Prospectus supplement with pricing info
4:22pm
S-1/A
46ojkwx6wka2wsj2d
1 May 23
IPO registration (amended)
6:10am
S-1/A
EX-1.1
gl07q2 tk3
1 May 23
IPO registration (amended)
6:10am
S-1
EX-2.1
gvg6 2q9t
13 Apr 23
IPO registration
5:10pm
S-1
u9pdaa kvutl5
13 Apr 23
IPO registration
5:10pm
- Prev
- 1
- Next